Femasys (FEMY) Research & Development (2020 - 2026)
Femasys' (FEMY) quarterly Research & Development came in at $1.9 million in Q2 2026, up 37.64% on a YoY basis from $1.4 million in Q2 2025, and up 37.64% quarter-over-quarter from $1.4 million in Q2 2025.
Analysis
Femasys (FEMY) Research & Development (2020 - 2026) Analysis & Trends
Femasys (FEMY) has reported Research & Development for 7 consecutive years, with $1.9 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Research & Development rose 37.64% year-over-year to $1.9 million; the trailing twelve-month figure through Jun 2026 stood at $8.5 million (down 4.03% YoY), and the FY2025 full-year result was $7.6 million, down 7.78% from the prior year.
- Research & Development grew to $1.9 million in Q2 2026 per FEMY's latest filing, from $1.4 million in the prior quarter.
- Across five years, Research & Development topped out at $3.0 million in Q1 2025 and bottomed at $1.3 million in Q4 2022.
- Historically, Research & Development has averaged $1.8 million across 5 years, with a median of $1.8 million in 2024.
- The widest YoY moves for Research & Development: up 67.64% in 2025, down 28.42% in 2025.
- Over 5 years, Research & Development stood at $1.3 million in 2022, then surged by 62.89% to $2.1 million in 2023, then grew by 4.61% to $2.2 million in 2024, then slumped by 34.72% to $1.4 million in 2025, then soared by 37.64% to $1.9 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $1.9 million, $1.4 million, and $3.0 million for Q2 2026, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | 892.00 Mn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | 370.60 Mn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | 771.00 Mn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | 434.00 Mn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | 554.00 Mn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | 278.90 Mn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | -663.00 Mn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | 153.00 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | 28.60 Mn |
| 10 | Femasys | 9.37 Mn | 7.92 Mn | 189,391.00 | 1.95 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.95 Mn |
| Jun 30, 2025 | 1.41 Mn |
| Mar 31, 2025 | 2.97 Mn |
| Dec 31, 2024 | 2.17 Mn |
| Sep 30, 2024 | 2.30 Mn |
| Jun 30, 2024 | 1.98 Mn |
| Mar 31, 2024 | 1.77 Mn |
| Dec 31, 2023 | 2.07 Mn |
| Sep 30, 2023 | 2.07 Mn |
| Jun 30, 2023 | 1.53 Mn |
| Mar 31, 2023 | 1.54 Mn |
| Dec 31, 2022 | 1.27 Mn |
| Sep 30, 2022 | 1.65 Mn |
| Jun 30, 2022 | 1.47 Mn |
| Mar 31, 2022 | 1.42 Mn |
| Dec 31, 2021 | 1.05 Mn |
| Sep 30, 2021 | 1.14 Mn |
| Jun 30, 2021 | 894,868.00 |
| Mar 31, 2021 | 995,022.00 |
| Dec 31, 2020 | 895,591.00 |